Featuring a slide presentation and related discussion from Dr Neeraj Agarwal, including the following topics:
- Therapeutic targets of systemic therapy in prostate cancer (0:00)
- Prevalence of genomic alterations in prostate cancer including PTEN deficiency; prognostic and predictive value (3:52)
- Optimal timing of and approach to PTEN assessment; pathophysiology surrounding PTEN loss (9:29)
- Comparison of ipatasertib and capivasertib; key findings from Phase III IPATential150 and CAPItello-281 studies (14:26)
- Safety and tolerability profile of capivasertib; strategies for management of adverse events (19:21)